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Abstract
Background—Male circumcision can reduce the risk of heterosexually-acquired HIV-1
infection in men. Neonatal male circumcision (NMC) has many potential advantages over
circumcision at older ages but little is known about its feasibility and safety in resource-limited
settings.
Methods—We performed a randomized trial in southeastern Botswana of Mogen clamp and
Plastibell, two commonly used devices for NMC. Follow-up visits occurred at six weeks and four
months postpartum. Adverse events, parental satisfaction and staff impressions were recorded.
Results—Of 302 male neonates randomized, 300 (99%) underwent circumcision, 153 (51%)
with Mogen clamp and 147 (49%) with Plastibell. There were no major adverse events in the
Mogen clamp arm but there were two major adverse events in the Plastibell arm (both were a
proximally migrated ring that had to be removed by study staff). Minor adverse events were more
common with the Mogen clamp compared with the Plastibell, specifically removal of too little
skin and formation of skin bridges or adhesions (12 vs. 1 and 11 vs. 3, respectively, all P<0.05).
Five (3%) infants in the Mogen clamp arm and none in the Plastibell arm had minor bleeding
(P=0.03). More than 94% of mothers reported being highly or completely satisfied with the
procedure.
Conclusions—NMC can be performed in Botswana with a low rate of adverse events and high
parental satisfaction. Although the risk of migration and retention of the Plastibell is small, the
Mogen clamp may be safer for NMC in regions where immediate emergent medical attention is
not available.
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Three large randomized trials have provided compelling evidence that male circumcision
(MC) reduces men's risk of heterosexually-acquired HIV-1 1-3. The World Health
Organization (WHO) recommends MC for HIV risk reduction, and states that “Since
neonatal circumcision is a less complicated and risky procedure than circumcision
performed in young boys, adolescents or adults ... countries should consider how to promote
neonatal circumcision in a safe, culturally acceptable and sustainable manner”4. Systematic
reviews have confirmed that the neonatal period or infancy are the safest time for MC to be
performed5, 6.
Except as part of religious custom, neonatal male circumcision (NMC) is rarely performed
in resource-limited settings, even in places where ritual circumcision is performed in older
age groups. Previous studies in Botswana have reported, however, that self-reported
acceptability of NMC among new mothers was more than 90%7. Building upon this finding,
we aimed to address the question of which technique would be safest and ultimately most
sustainable for programmatic scale-up of NMC in Botswana. Although specialized devices
are utilized for NMC in well-resourced settings to improve the safety of the procedure, none
has been carefully studied in resource-limited settings. Commonly-used devices (in
circumcising regions) include the Gomco Clamp, the Mogen Clamp and the Plastibell.
Based on the results of previous clinical studies regarding the respective ease of use of the
devices 8, 9, we elected to evaluate Mogen clamp and Plastibell.
Methods
Study Design
This randomized clinical trial was designed to evaluate Mogen clamp and Plastibell as
candidates for scale-up of NMC programs in sub-Saharan Africa. The study was approved
by the Botswana Ministry of Health's Health Research and Development Committee
(HRDC) and by Brigham and Women's Hospital Institutional Review Board (IRB). Written
informed consent was obtained from the mothers or their legal guardians (if mothers were <
21 years, age of majority in Botswana) before neonates underwent randomization.
Subjects
Mothers and infants were enrolled between May 2009 and December 2010 at three hospitals
in southeastern Botswana: Princess Marina Hospital in the capital city Gaborone, Scottish
Livingstone Hospital in the village of Molepolole, and Deborah Retief Memorial Hospital in
the village of Mochudi. Eligible mothers and infants were identified by study staff during
visits to the maternity wards in the respective hospitals. Maternal eligibility criteria were
Botswana citizenship, non-incarceration and ability to follow-up for four months. Infant
eligibility criteria were male gender, gestational age ≥ 37 weeks, age ≤ 28 days of life, birth
weight ≥ 2,500 grams, no evidence of neonatal sepsis or other illness requiring
hospitalization, no family history of bleeding disorder, no genital or other abnormality that is
a contraindication to NMC.
Randomization and Study Interventions
Infants were randomized centrally (using permuted blocks of 10 within each site) after they
were brought to the study site for the procedure. Study staff performed a physical exam to
exclude infants with abnormalities precluding circumcision.
All infants had approximately one gram of eutectic mixture of local anesthetic (EMLA)
applied to penis and covered with an occlusive dressing10; EMLA was wiped off prior to the
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procedure. Infants’ upper bodies and arms swaddled, and legs restrained by an assistant.
Infants had the genital area, lower abdomen and upper legs cleansed with chlorhexidine
immediately prior to NMC. During the procedure, infants were given concentrated sucrose
solution either by gloved finger or by syringe to augment the anesthetic effect of EMLA, as
has been previously described11-13. All infants were given Vitamin K at birth, the standard
of care in Botswana.
All circumcisions were performed by a study physician (NN) using clean, rather than sterile,
techniques, as had been previously documented to be very safe14, 15. The study physician,
who had no significant prior experience in performing NMC, was trained by a pediatric
urologist prior to the study initiation and was deemed competent with both devices. All
infants were circumcised in accordance with the WHO's “Manual for early infant male
circumcision under local anaesthesia”16 and described by our group previously17. Briefly,
the Mogen clamp is a reusable stainless steel device that requires a new, sterile scalpel blade
for each NMC. The scalpel blades used for the study were all new (disposed after one use).
The Plastibell is a disposable plastic device that comes in six sizes (1.1 – 1.7 cm diameter)
and requires stainless steel scissors (the scissors may be reusable after proper disinfection).
Both devices additionally require stainless steel lacrimal duct probes and hemostats.
Between uses, the scissors, lacrimal duct probes, hemostats and Mogen clamps all
underwent high-level disinfection. All infants had the wound dressed with gauze and
Vaseline. All reusable instruments were disinfected with bleach as per WHO protocol,
scrubbed with soap and water and then disinfected with Cidex Opa according to the
instructions for high-level disinfection provided in the package insert.
After circumcision, infants were checked for post-procedure bleeding or other immediate
complications. Mothers were asked to wait with the infant for two hours following the
procedure prior to leaving the facility to ensure there was no excessive bleeding and that the
infant had urinated. Mothers were given Vaseline for wound care and written post-procedure
care instructions that included a phone number to reach a physician 24 hours a day, seven
days a week, in case of any questions or concerns.
Follow-up and Evaluation
Post-procedure follow-up visits were planned to coincide with the national vaccination /
well-baby visits at six weeks and four months of infant age. At these visits, parents were
asked about complications and child outpatient cards were also reviewed for evidence of
visits to non-study clinics or providers for adverse events potentially related to the
procedure. At each follow-up, infants also had a physical exam, including inspection of the
circumcision, by the study physician.
Outcomes
The primary study outcomes were adverse events and parental satisfaction by randomization
arm. Secondary outcomes included staff impressions of the comparative safety, tolerability,
and ease of use of the two techniques. We also measured the time taken to perform the
procedure from the infant's diaper being removed until the time it was replaced, and
recorded the number of Plastibells opened so that correct sizing could be achieved.
Adverse events that were potentially related to NMC were defined prior to study initiation
and categorized as bleeding, infection, structural and other. Bleeding requiring only the
application of pressure beyond the immediate post-procedure period was defined as a minor
adverse event. Intervention other than pressure (e.g. suturing) was defined as a moderate
adverse event. A separate clinic visit or hospitalization for bleeding from the circumcision
site or need for IV fluids or blood products were categorized as major adverse events.
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Infection limited to the circumcision site was defined as a minor adverse event. Soft-tissue
infection spreading beyond the penis (lower abdominal wall, upper legs) was defined as a
moderate adverse event. Systemic infection / sepsis was defined as a major adverse event.
Removal of too much or incorrect tissue; removal of too little tissue requiring repeat
procedure; or structural injury to glans, urethra or shaft were defined as major adverse
events, as were subsequent problems with urination or proximal migration / retention of a
Plastibell ring requiring intervention for removal.
As to parental satisfaction, we asked parents to complete a structured questionnaire about
their experiences with the procedure at the follow-up visits (including potential problems,
and satisfaction measured by a visual analogue scale from 0 – 100%). We defined highly or
completely satisfied as a score of 90% or greater. We asked whether parents would be likely
to choose NMC for a future son and how likely parents would be to recommend the
procedure to a relative or a friend who had a baby boy.
After all participant follow-up visits were completed, study staff were asked to fill-out a
short semi-structured questionnaire of their subjective impressions of the two devices.
Statistical Analysis and Safety Monitoring
This study was designed to detect a 20% difference in parental satisfaction between the two
techniques with 90% power assuming a significance level of 0.05 and two-sided statistical
test. This study was not powered to detect a statistically significant difference in major
adverse events between the two devices (with previously reported rates of major
complications as low as 0.2% in well-resourced settings, approximately 12,750 infants per
arm would be required to detect a doubling in the complication rate)14, 18. Instead, this study
was designed to provide preliminary and descriptive data on the safety and sustainability of
the Plastibell and Mogen clamp in Botswana that could be used to guide larger safety
studies.
Differences in baseline characteristics between randomization arms were assessed using
Fisher's exact test for dichotomous and categorical variables and Student's t-test for
continuous variables. Analysis of primary outcomes of interest occurred only for infants
who underwent circumcision. We compared parental satisfaction between randomization
arms at six weeks and four months using Fisher's exact test. All statistical analyses were
performed with SAS software version 9.2 (SAS Institute, Cary, NC).
An independent Data Safety Monitoring Committee (DSMC) was responsible for analyzing




Between May 2009 and December 2010 there were a total of 1,200 eligible mother / son
pairs in the three maternity wards. Working within daily time constraints, our staff invited
808 mothers to participate in the study; 547 (68%) agreed to complete the initial
questionnaire and 506 (93%) said they would want NMC. Of these 506, 302 (60%) brought
their neonate for NMC and provided written informed consent for the procedure (100/129
[78%] in Mochudi, 102/163 [63%] in Molepolole and 100/255 [39%] in Gaborone).
All 302 infants were enrolled and randomized: 155 to Mogen clamp and 147 to Plastibell.
Demographic and clinical characteristics between the randomized groups were well
balanced (Table 1). The maternal self-reported HIV status matched national prevalence rates
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for Botswana19. Overall, 166 (55%) mothers chose to have NMC before hospital discharge
and 136 (45%) chose to return from home for NMC.
Two neonates, randomized to Mogen clamp, were not circumcised because they developed
fever after randomization making them ineligible for the procedure. Therefore, 300 infants
were circumcised (153 by Mogen, 147 by Plastibell). All infants were evaluated for
immediate complications. A total of 295 (98%) infants had at least one subsequent follow-
up visit and 258 (86%) infants completed both scheduled study visits (87% of Mogen clamp
arm and 85% of Plastibell arm, P=0.6). Of the five infants with no follow-up after the
immediate post-procedure assessment, two moved out of the study area (mothers reported by
phone that babies were well) and three died (Figure 1). Of these, two died of gastroenteritis
and one died of suspected neonatal sepsis on his second day of life, with the death reviewed
by the study DSMC, Botswana HRDC and Brigham and Women's Hospital IRB and not
thought to be procedure-related.
Procedures
No adverse events were associated with the EMLA / sucrose anesthesia. The median
duration of EMLA cream application was 73 minutes, absolute range 10 – 286 minutes.
NMC with Mogen clamp required significantly less time than with Plastibell (P<0.0001).
The Mogen clamp required a mean of 5.5 minutes (95% confidence interval [CI] 5.1 – 5.8);
median of 5 minutes (IQR 4-6), total range 2 – 18 minutes versus Plastibell which required a
mean of 7.2 minutes (95% CI 6.9 – 7.5); median 7 minutes (IQR 6-8) total range 4 – 17. The
time required for the provider to perform an individual procedure did not change in either
arm over the course of the study.
In 86 (59%) of Plastibell cases, only one device was opened to complete the procedure
correctly with the appropriately-sized bell. In 58 (40%) of cases two Plastibells were opened
and in three cases (2%) three Plastibells were opened for a total of 211 devices opened to
complete 147 procedures.
Parents reported a median of seven days until the Plastibell ring fell off (IQR 5-8), with a
range from 2-14 days.
Adverse Events
We observed 34 adverse events among 30 infants (10%), with four having two adverse
events (Table 2). Two of the 30 experienced a major adverse event from Plastibells that
migrated proximally to the corona. In each of these cases the ring had to be removed by the
study staff (Figure 2), one at day 14and one at day 17. Neither infant suffered sequelae from
the ring retention.
The most common adverse event was removal of too little skin (27 cases), as defined by
incomplete visualization of the glans (< ½ glans visible) (13 cases), or formation of
adhesion / skin bridge (14 cases). Each of these minor adverse events was significantly more
common with Mogen clamp than with Plastibell (Table 2). Five (3.2%) infants in the Mogen
clamp arm, but none in the Plastibell arm, had minor bleeding immediately after the
procedure (all controlled with local pressure) (P=0.03). No other bleeding episodes were
reported.
No local or systemic infections were reported, and there were no cases in which too much
skin (defined as > ½ shaft denuded) was removed, nor were there other structural
complications. As noted earlier, none of the three infant deaths was judged to be procedure-
related.
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The rate of complications declined over the study period by approximately 0.88
complications / 100 procedures per month (P=0.0004) (Figure 3).
Parental Satisfaction
Of 278 infants completing the six-week follow-up visit, 96% of mothers whose neonate was
circumcised with the Mogen clamp and 95% of those whose neonates were circumcised with
the Plastibell reported being highly or completely satisfied with the procedure (P=0.5). Of
278 mothers completing the four-month follow-up visit, 95% of those whose neonate was
circumcised with the Mogen clamp and 99% of those whose neonates were circumcised with
the Plastibell reported being highly or completely satisfied with the procedure (P=0.04).
Regardless of randomization arm, between 96% and 99% of mothers stated they would
recommend highly or completely the procedure to a friend or relative. Regardless of
randomization arm, at least 97% of mothers reported that they would want NMC for another
neonate should they have one.
Sixteen fathers whose neonate was circumcised with Mogen clamp responded to the four-
month questionnaire: 16 (100%) were highly or completely satisfied and would recommend
NMC to a friend or relative; 15 (94%) would circumcise a future son. Eleven fathers whose
neonate was circumcised with Plastibell responded to the four-month questionnaire: all 11
(100%) were highly or completely satisfied, would recommend NMC to a friend or relative
and would circumcise a future son.
Mothers whose infants had experienced a complication were significantly less likely to be
highly or completely satisfied at six weeks (24/28 versus 242/250, P=0.006) and at four
months (24/30 versus 246/248, P<0.0001). Both mothers whose infant had a Plastibell
retained were 100% satisfied at four months.
Staff Impressions
The physician who performed all NMCs and the five nurses and three recruiters who
assisted him in the procedures all completed a questionnaire regarding their impressions. All
nine staff members reported a subjective impression that the Mogen clamp was better
tolerated by the baby based on length of the procedure and their impression of infant
distress. Six of nine staff considered the Mogen procedure as easier to perform, one believed
that the Plastibell was easier, and two felt that the two devices were similarly easy to use.
Five staff thought the Plastibell was safer than the Mogen clamp; three thought the Mogen
clamp was safer; and one thought the two were equally safe. Five staff thought the neonate's
family preferred the Mogen; one thought the Plastibell was preferred; and three thought
there was no difference in family preference. When asked which device they would want
used for their own child, four would choose Plastibell; two would choose Mogen clamp; and
three had no preference. When asked which device should be used for program scale-up,
four would choose Mogen clamp; three would choose Plastibell; and one had no preference.
Discussion
We performed the first randomized study of Mogen clamp and Plastibell for NMC in a
resource limited setting using clean techniques and found the procedure to have a low rate of
adverse events. Reported acceptability of the procedure was high (93% of those interviewed)
and although actual uptake of the procedure in our study (55% of all study participants) was
higher than that previously reported in sub-Saharan settings (11%)20, more must be learned
about barriers to uptake for scale-up to be successful. Parents reported a high level of
satisfaction with NMC and it is possible that, with increased knowledge about and
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experience with NMC in this setting, parents will be more likely to choose the procedure for
their sons.
Although this study was not powered to detect a statistically significant difference in adverse
events, several important differences were found between the Mogen clamp and the
Plastibell. The rate of major adverse events was low overall and was limited to
circumcisions done with the Plastibell. Because of the potential for serious morbidity and
even mortality if a neonate with a retained Plastibell is not brought quickly to medical
attention, we defined a retained Plastibell as a major adverse event. Potential complications
of a retained Plastibell include, but are not limited to, urinary retention, bladder rupture and
necrosis of the glans 21, 22. Almost all potential complications with the Mogen happen
during or immediately following the procedure, while migration and retention of the
Plastibell is a late complication and would depend on caregiver recognition and subsequent
management by local (sometimes remote) health facilities. Therefore, the Plastibell might
not be a good choice for use in areas with low medical literacy or poor access to emergency
medical services.
We observed more minor adverse events with the Mogen clamp compared to the Plastibell,
the most frequent one was too little skin being removed. This complication became less
common as the study progressed and as the provider became more comfortable with the
instrument and better able to gauge how much tissue to remove. The use of a surgical pen,
recommended for NMC by the WHO, to mark the corona and delineate landmarks prior to
the procedure, could reduce the frequency of this complication 16. This study was conducted
prior to the publication of WHO guidelines and a surgical pen was not used. We would
strongly recommend the use of a surgical pen for all NMC procedures to avoid the problem
of removing too little skin; if not enough foreskin is removed, the protective effect of male
circumcision against HIV and other sexually transmitted infectious could be reduced.
Although we did not observe any injury to the glans in our study, partial amputation of the
glans has been reported with the Mogen clamp23-25. We did not observe excess bleeding
with the Plastibell, but this too has been reported16.
One drawback to both techniques is that, other than the disposable Plastibell and a
disposable scalpel blade, all instruments require high-level disinfection or sterilization
between successive uses. Another logistic complexity that must be considered with the
Plastibell is the importance of having all six sizes available at all times: bells that are too
large or too small for the child may be more likely to result in complications such as
proximal migration and retention, highlighting the importance of supply-chain management.
This is especially crucial for NMC programs because successful scale-up will depend on
providing the services at local health facilities where women either deliver or bring babies
for vaccinations. Remote health facilities would have to be able to maintain an adequate
supply chain to ensure safety.
Staff involved in the study universally thought the Mogen clamp was better tolerated by the
baby than the Plastibell (and indeed the procedure duration was significantly shorter with the
Mogen clamp). The only previously published randomized study of Mogen clamp and
Plastibell, which was conducted in the United States, reported that the Mogen clamp was
“associated with less pain and discomfort [for the infant]”26.
Finally, the issue of neonatal mortality must be addressed. In many parts of sub-Saharan
Africa neonatal mortality rates continue to be unacceptably high and may be slow to decline.
Where diagnostic capabilities are limited, it can be difficult to make a definitive diagnosis as
to the cause of a neonate's death. Therefore, we would strongly recommend that if a provider
detects any sign of neonatal illness, that the NMC procedure be postponed until the neonate
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is deemed clinically well. Although NMC has been shown to be very safe in resource-rich
settings14, 18 and should be equally safe in resource-limited settings, it is important that
providers perform NMC only when the risks of the procedure can be absolutely minimized,
and that the public be educated about the safety of NMC so that neonatal deaths are not
erroneously attributed to the procedure.
Limitations
The study was small and therefore unable to detect all potential adverse events that might
occur with programmatic scale-up of NMC. Programmatic monitoring and evaluation of
uptake, outcomes and complications will be necessary as the procedure is taken to scale to
ascertain true rates of adverse events.
Also, in order to study the devices themselves while reducing other variables that could
influence outcomes, one trained physician performed all the NMCs, therefore our results
may not be applicable to settings where non-physicians would be performing the procedure.
Furthermore, our procedures were performed in on the premises of district hospitals and our
findings may not be generalizable to lower-resourced clinical settings.
Although fathers can be important decision makers with regard to MC27, 28, few fathers
participated in our study; at the time of delivery less than 30% of women were married to or
cohabitating with a partner. Furthermore, in Botswana there is a traditional period of
confinement for mothers and infants during which fathers are discouraged from visiting.
This may have reduced the availability of fathers to participate in the follow-up visits.
Conclusions
Neonatal male circumcision conducted under clean, rather than sterile, conditions can be
performed safely in Botswana. We observed only two major adverse events, both being a
proximally migrated, retained Plastibell ring that had to be removed by study staff. In areas
with limited access to emergency medical care, we consider the Mogen clamp to be a safer
choice than the Plastibell for public sector scale up in HIV-prevention programs. Innovative
devices for NMC that would improve the safety and reduce the complexity of disinfection
and supply-chain management would be an important advance for use in resource-limited
settings.
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Study Schema of Randomization and Follow-Up
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Plastibell ring that has migrated and lodged proximal to the corona being removed with ring
cutter
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Complication rate / 100 procedures by month of the study
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Table 1
Baseline Characteristics of Study Population by Randomization Arm
Mogen (N = 155) N (%)
a
Plasti Bell (N = 147) N (%)
a
Maternal Age (years), median (IQR) 28 (24 – 33) 28 (25 – 32)
Mothers married and / or cohabitating 37 (23.9%) 43 (29.3)
Maternal self-reported HIV infected 62/155 (41.1%) 51/147 (35.4)
Mother on ARVs 37/62 (60%) 26/51 (51%)
Neonatal Gestational Age at delivery (weeks), median (IQR) 39 (38-41) 39 (38-39)
Neonatal Birth Weight (kilograms), median (IQR) 3.2 (2.9-3.5) 3.2 (3.0 – 3.6)
Neonatal Age (days) at circumcision, median (IQR) 4 (2-11) 2 (2-5)
Site
    Gaborone 50 (32.3%) 50 (34.0%)
    Mochudi 51 (32.9%) 49 (33.3%)
    Molepolole 54 (34.8%) 48 (32.7%)
a
Column % unless otherwise noted
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Table 2
Complications by Randomization Arm
Mogen (=153) N (%)
a Plastibell (N=147) N (%) P
b
Bleeding 5 (3.2) 0 0.03
    Minor 5 0
    Moderate / Severe 0 0
Infection 0 0
Too Little Skin Removed 23 (14.7) 4 (2.7) < 0.01
    < ½ glans visible 12 (7.6) 1 (0.7) <0.01
    Adhesion / Skin Bridge 11 (7.0) 3 (2.0) 0.03
Too Much Skin Removed 0 0
Plastibell proximal migration N/A 2 (1.3)
a
Column % unless otherwise noted
b
Chi square
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